Wells Fargo & Company Cuts Teladoc Health (NYSE:TDOC) Price Target to $6.00

Teladoc Health (NYSE:TDOC) had its price target trimmed by Wells Fargo & Company from $8.00 to $6.00 in a research note published on Thursday,Benzinga reports. The firm currently has an equal weight rating on the health services provider’s stock.

TDOC has been the subject of several other reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Teladoc Health in a research note on Monday, December 29th. Zacks Research cut shares of Teladoc Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Stifel Nicolaus decreased their price target on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Thursday. Bank of America lowered their price target on shares of Teladoc Health from $9.00 to $8.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 25th. Finally, Barclays started coverage on shares of Teladoc Health in a report on Tuesday, December 9th. They issued an “equal weight” rating and a $8.50 price objective for the company. Four investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $7.80.

Teladoc Health Stock Down 1.8%

TDOC stock opened at $5.25 on Thursday. Teladoc Health has a 52 week low of $4.40 and a 52 week high of $9.94. The company has a quick ratio of 2.60, a current ratio of 2.70 and a debt-to-equity ratio of 0.71. The firm has a 50-day simple moving average of $5.99 and a 200-day simple moving average of $7.20. The stock has a market capitalization of $932.25 million, a P/E ratio of -4.61 and a beta of 2.12.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. Teladoc Health had a negative return on equity of 9.09% and a negative net margin of 7.92%.The company had revenue of $642.27 million for the quarter, compared to analysts’ expectations of $635.33 million. During the same period in the previous year, the firm posted ($0.28) EPS. Teladoc Health’s revenue was up .3% compared to the same quarter last year. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Equities analysts forecast that Teladoc Health will post -1.16 earnings per share for the current fiscal year.

Insider Activity

In other Teladoc Health news, insider Adam C. Vandervoort sold 5,720 shares of the firm’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total transaction of $42,842.80. Following the completion of the sale, the insider owned 80,732 shares of the company’s stock, valued at $604,682.68. This trade represents a 6.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Carlos Nueno sold 3,897 shares of the company’s stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $7.49, for a total value of $29,188.53. Following the completion of the transaction, the insider directly owned 27,175 shares in the company, valued at approximately $203,540.75. This trade represents a 12.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 33,288 shares of company stock worth $251,684 over the last quarter. 0.58% of the stock is currently owned by corporate insiders.

Institutional Trading of Teladoc Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TDOC. Teacher Retirement System of Texas boosted its position in shares of Teladoc Health by 5.7% during the second quarter. Teacher Retirement System of Texas now owns 26,592 shares of the health services provider’s stock worth $232,000 after buying an additional 1,431 shares during the period. Federated Hermes Inc. boosted its holdings in Teladoc Health by 0.5% during the 3rd quarter. Federated Hermes Inc. now owns 307,700 shares of the health services provider’s stock valued at $2,379,000 after acquiring an additional 1,450 shares during the period. Creative Planning boosted its holdings in Teladoc Health by 7.7% during the 3rd quarter. Creative Planning now owns 20,567 shares of the health services provider’s stock valued at $159,000 after acquiring an additional 1,462 shares during the period. Krane Funds Advisors LLC grew its position in Teladoc Health by 13.4% in the 3rd quarter. Krane Funds Advisors LLC now owns 12,431 shares of the health services provider’s stock valued at $106,000 after acquiring an additional 1,469 shares in the last quarter. Finally, State of Wyoming increased its stake in Teladoc Health by 2.1% during the third quarter. State of Wyoming now owns 79,075 shares of the health services provider’s stock worth $611,000 after purchasing an additional 1,628 shares during the period. Hedge funds and other institutional investors own 76.82% of the company’s stock.

More Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 beat and narrower loss — Teladoc posted Q4 revenue of $642.3M (above Street) and a GAAP loss of $0.14/sh that was better than expected; management highlighted international and Integrated Care strength that helped offset weakness at BetterHelp. Teladoc Tops Q4 Earnings
• Positive Sentiment: Medium‑term revenue guidance and strategic initiatives — Management projected 2026 revenue of $2.47B–$2.59B and emphasized AI, insurance partnerships and international expansion as growth levers. That gives investors a multi‑year growth narrative beyond the quarter. 2026 Revenue Projection
• Positive Sentiment: Some analyst support remains — Bank of America upgraded TDOC to Buy (PT $7) and a few firms (Canaccord, Piper Sandler) kept positive/overweight stances despite trimming targets, signaling conviction among some analysts that upside exists from current levels. Analyst Reviews
• Neutral Sentiment: Earnings call details and metrics — Management’s earnings call and transcript provide context on segment trends (Integrated Care up, BetterHelp down) and KPI performance; useful for assessing sustainability of the beat. Earnings Call Highlights
• Negative Sentiment: Near‑term guidance and outlook caution — Q1 revenue guide (~$609M) and FY EPS guidance were conservative and Q1 revenue guidance came in below some estimates, creating uncertainty over short‑term growth and profitability. Q4 & Guidance Release
• Negative Sentiment: Multiple price‑target cuts — Several firms trimmed targets (examples: BMO to $5.00, Leerink to $5.50, Cowen/Wells Fargo/Stifel to $6.00 ranges), and some moved to market‑perform/hold — this fresh downdraft from sell‑side revisions pressures sentiment despite the beat. Analyst Target Moves

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.